By liberating vascular endothelial growth factor (VEGF) from angiogenic islets, MMP-9 is known to initiate the angiogenic migration in cancer, [45] whereas MMP-2 controls the bioavailability of dissolved VEGF-A and tumor vascular patterning [46]. This evidence concerns the gene VEGFA and neoplasm.